Baxter International Inc. BAX recently announced that the FDA has approved its AMIA automated peritoneal dialysis (APD) system with the SHARESOURCE web-based remote connectivity platform.
Peritoneal dialysis is a medical procedure to remove waste products from a patient’s blood when the kidneys are not entirely functional.
Baxter joined forces with DEKA Research and Development Corporation (DEKA) to develop the AMIA APD system, which offers peritoneal dialysis for patients suffering from end-stage renal disease (ESRD). Baxter expects to roll out the product this year.
Notably, AMIA APD system is the only FDA approved product in the U.S. that possesses patient-friendly features such as voice guidance, a touchscreen control panel and the SHARESOURCE two-way connectivity platform.
With the help of the SHARESOURCE platform, physicians will be able to efficiently access the past treatment data of home patients and provide individual prescriptions remotely.
AMIA APD system comes with sophisticated, animated graphics and automatic step-by-step commands, which is built to increase the effectiveness of home therapy guidance and management for ESRD patients.
Reportedly, more than 600,000 individuals are currently suffering from ESRD and are in dire need of peritoneal dialysis. According to a report by market research firm MarketsandMarkets, the global peritoneal dialysis market is expected to reach a worth of approximately $83.21 billion by 2018. The favorable market trend thus presents significant growth opportunities for Baxter.
However, the peritoneal dialysis market is rife with competition with players like Fresenius Medical Care AG & Co. KGAA FMS and Nxstage Medical NXTM.
Zacks Rank and Another Key Pick
Currently, Baxter has a Zacks Rank #1 (Strong Buy). Another well-placed stock in the Medical Products industry is NuVasive NUVA, with a Zacks Rank #1.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Be the first to comment